Hüseyin TUTKAK, A. Olcay TİRYAKİ, Nurşen DÜZGÜN, N. Defne ALTINTAŞ

An analysis of the relationship between different autoantibodies and clinical findings in a group of Turkish patients with systemic lupus erythematosus

Amaç: Sistemik lupus eritematozuslu (SLE) bir grup Türk hastada farklı antikardiyolipin antikor izotiplerinin (aCL), anti-C1q antikor (anti-Cq1) ve antibeta2- glikoprotein 1 IgG (anti-b2GP1 IgG) antikor sıklığının ve lupus nefriti ve ekstra-renal tutulum ile ilişkisinin incelenmesi. Hastalar ve Yöntemler: Ankara Üniversitesi Tıp Fakültesi, Klinik İmmünoloji ve Romatoloji departmanında Mayıs 2001 – Mayıs 2002 tarihleri arasında değerlendirilen SLE’li hastalar çalışmaya dahil edildi. Hemodiyaliz ihtiyacı olanlar çalışma dışında tutuldu. Hastalık süreleri, ilaçları, organ tutulumları, hastalık komplikasyonları ve laboratuvar sonuçları kaydedildi. Hastalık aktivitesi SLEDAI ile değerlendirildi; skorun ≥ 4 olması aktif hastalık olarak kabul edildi. Antikor titreleri enzim immunoassay yöntemiyle değerlendirildi. Bulgular: Toplam 62 hasta (51 kadın, 11 erkek) çalışmaya alındı. Ortalama yaş 37; ortalama hastalık süresi 104 aydı. Hastaların %55’inin SLEDAI skoru ≥ 4’tü. Renal tutulum %76’sında, aktif nefrit %49’unda saptandı. Tromboz %11’inde, obstetrik komplikasyonlar %16’sında, nörolojik komplikasyonlar %37’sinde, trombositopeni %26’sında, Raynaud fenomeni %45’inde mevcuttu. Antikorların hiçbiri renal tutulum ile ilişkili bulunmadı. SLEDAI ≥ 4 olanlarda toplam aCL pozitifliği anlamlı olarak yüksekti (p

Sistemik lupus eritematozuslu bır grup Türk hastada farklı otoantikorlar ve klinik bulgular arasındaki ilişkinin incelenmesi

Purpose: To study the prevalence of different anticardiolipin antibody isotypes (aCLs), anti-C1q antibodies (anti-C1q), and anti-b2-glycoprotein 1 IgG antibodies (anti-b2GP1 IgG) in a group of Turkish SLE patients and their association with lupus nephritis and extra-renal involvement. Materials and Methods: SLE patients who were evaluated in Ankara University Faculty of Medicine, Department of Clinical Immunology and Rheumatology between May 2001 and May 2002 were included in the study, unless they were also hemodialysis patients. Disease duration, medications, organ involvement, disease complications and follow-up laboratory results were recorded. Disease activity was evaluated with SLEDAI; a score of ≥ 4 indicated active disease. Antibody titers were determined using the enzyme immunoassay method. Results: A total of 62 patients (51 women, 11 men) were included. The mean age was 37. Average duration of illness was 104 months. Of the patients, 55% had a SLEDAI score of ≥ 4. Renal involvement was present in 76%, with active nephritis in 49%. Thrombosis was present in 11%, 16% had obstetric complications, 37% had neurologic findings, 26% had thrombocytopenia, and 45% had Raynaud’s phenomenon. None of the antibodies were related to renal involvement. Patients with SLEDAI ≥ 4 had significantly increased total aCL positivity (p

PDF

___

1. Edworthy SM. Clinical manifestations of systemic lupus erythematosus. In: Ruddy S, Harris ED Jr, Sledge CB, eds. Kelley’s Textbook of Rheumatology, Philadelphia: W. B. Saunders, 2001; 1105-1124.
2. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1000 patients. Medicine 1993; 72: 113-124.
3. Frontiers of SLE: Review of the 5th international congress on SLE, Cancun, Mexico, April 20-25, 1998. Semin Arthritis Rheum 1999;29: 112-130.
4. Swaak AJG, Brink HG, Smeenk RJT, et al. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology 1999; 38: 953-958.
5. Berden JHM. Lupus nephritis. Kidney Int 1997; 52: 538-558.
6. Mannik M, Wener MH. Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. Arthritis Rheum 1997; 40: 1504-1511.
7. Siegert C, Daha M, Westedt ML, et al. IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and ds- DNA antibodies in systemic lupus erythematosus. J Rheumatol 1991; 18: 230-234.
8. Siegert CEH, Kazatchkine MD, Sjöholm A, et al. Autoantibodies against C1q: view on clinical relevance and pathogenic roles. Clin Exp Immunol 1999; 116: 4-8.
9. Gunnarsson I, Sundelin B, Heimbürger M, et al. Repeated renal biopsy in proliferative lupus nephritis-predictive role of serum C1q and albuminuria. J Rheumatol 2002; 29: 693-9.
10. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-1214.
11. İnanç M, Radway-Bright EL, Isenberg DA. b2-glycoprotein I and anti-b2-glycoprotein I antibodies: Where are we now? Br J Rheumatol 1997; 36: 1247-1257.
12. Triplett DA. Antiphospholipid antibodies. Arch Pathol Lab Med 2002; 126: 1424-1429.
13. Davies ML, Young SP, Welsh K, et al. Immune responses to native b2-glycoprotein I in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Rheumatology 2002; 41: 395-400.
14. Visvanathan S, McNeil HP. Cellular immunity to b2-glycoprotein I in patients with the antiphospholipid syndrome. J Immunol 1999;162: 6919-6925.
15. Sebastiani GD, Galeazzi M, Tincani A, et al. Anticardiolipin and anti-b2-glycoprotein I antibodies in a large series of European Patients with Systemic Lupus Erythematosus. Scand J Rheumatol 1999;28: 344-351.
16. Frampton G, Hicks J, Cameron JS. Significance of antiphospholipid antibodies in patients with lupus nephritis. Kidney Int 1991; 39:1125-1231.
17. Loizou S, Samarkos M, Morsworthy PJ, et al. Significance of anticardiolipin and anti-b2-glycoprotein I antibodies in lupus nephritis. Rheumatology 2000; 39: 962-968.
18. Wakai S, Matsumura O, Koike T, et al. Anticardiolipin antibody and renal microthrombi in lupus nephritis. Ryumachi 1991; 5: 481-487.
19. Tubach F, Hayem G, Marchand JL, et al. IgG anti-b2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol 2000; 27: 1437-1443.
20. De Bandt M, Benali K, Guillevin L, et al. Longitudinal determination of antiphospholipid antibodies in lupus patients without previous manifestations of antiphospholipid syndrome. A prospective study. J Rheumatol 1999; 26: 91-96.
21. Moroni G, Trendelenburg M, Del Papa N, et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 2001; 37: 490-498.
22. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
23. Bombardier C, Dladman DD, Urowitz MB, et al. Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
24. Petri M, Genovese M, Engle E, et al. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. Arthritis Rheum 1991; 34: 937-944.
25. Cortes-Hernandez J, Ordi-Ros J, Labrador M, et al. Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus. Am J Med 2004; 116: 165-173.
26. Tsutsumi A, Matsuura E, Ichikawa K, et al. Antibodies to b2- glycoprotein and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39: 1466-1474.
27. Alarcon-Segovia D, Mestanza M, Cabiedes J, et al. The antiphospholipid/ cofactor syndromes. II. A variant in patients with systemic lupus erythematosus with antibodies to b2-glycoprotein I but no antibodies to detectable in standart anti-phospholipid assays. J Rheumatol 1997; 24: 1545-1551.
28. Keane PA, Ravikumar K, O’Shea SI, et al. Anti-b2-glycoprotein I and the anti-phospolipid syndrome. Am J Ophthalmol 2006; 142:701-702.
29. Cabiedes J, Cabral AR, Alarcion-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-b2-glycoprotein I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899-1906.
30. Bruce IN, Soloninka CAC, Spitzer K, et al. Prevalence of antibodies to b2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid syndrome criteria: a single center study and literature review. J Rheumatol 2000; 27: 2833-2837.
31. İnanç M, Donohoe S, Ravirajan CT, et al. Anti-b2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome. Br J Rheumatol 1998; 37: 1089-1094.
32. Voss A, Jacobsen S, Heegard NHH. Association of b2-glycoprotein I IgG and IgM antibodies with thrombosis and thrombocytopenia. Lupus 2001; 10: 533-538.
33. Audrain MAP, El Kouri D, Hamidou MA, et al. Value of autoantibodies to b2-glycoprotein I in the diagnosis of antiphospholipid syndrome. Rheumatology 2002; 41: 550-553.
34. Perez-Vazquez ME, Villa AR, Drenkard C, et al. Influence of disease duration, continued follow-up and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus. J Rheumatol 1993; 20: 437-442.
35. Bertolaccani ML, Atsumi T, Contreras AE, et al. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 2001; 28:2637-2643.
36. Gunnarson I, Rönnelid J, Huang YH, et al. Association between ongoing Anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus. Br J Rheumatol 1997; 36: 32-37.
37. Norsworthy P, Theodoridis E, Botto M, et al. Overrepresentation of the FCb receptor type IIA R131/R131 genotype in caucasoid systemic lupus erythematosus patients with autoantibodies to C1q and glomerulonephritis. Arthritis Rheum 1999; 42: 1828-1832.
38. Gunnarsson I, Rönnelid J, Lundberg I, et al. Occurrence of anti-C1q antibodies in IgA nephropathy. Nephrol Dial Transplant 1997; 12:2263-2268.
39. Trendelenburg M, Marfurt J, Gerber I, et al. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum 1998; 42: 187-188.
40. Kumar A, Gupta R, Varghese T, et al. Anti-C1q antibody as a marker of disease activity in systemic lupus erythematosus. Indian J Med Res 1999; 110: 190-193.
41. Reveille JD. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus 2004; 13: 290-297.
42. Siegert CEH, Daha MR, Halma C, et al. IgG and IgA autoantibodies to C1q in systemic and renal diseases. Clin Exp Rheumatol 1992; 10:19-23.
43. Huong DLT, Papo T, Beaufils H, et al. Renal involvement in systemic lupus erythematosus. Medicine 1999; 78: 148-166.
44. Foster MH, Kelley VR. Lupus nephritis: update on pathogenesis and disease mechanisms. Semin Nephrol 1999; 19: 173-181.
45. Fofi C, Cuadrado MJ, Godfrey T, et al. Lack of association between antiphospholipid antibody and WHO classification in lupus nephritis. Clin Exp Rheumatol 2001; 19: 75-77.
46. Sahin M, Duzgun N, Tunc SE, Tutkak H. Antibodies to beta2- glycoprotein-I: relation of anticardiolipin antibodies with clinical and laboratory parameters in patients with systemic lupus erythematosus. Clin Biochem 2007; 40: 526-530.